Karolinska Development
-
Spine
Karolinska Development’s portfolio company OssDsign has received FDA clearance for a new major indication
STOCKHOLM, SWEDEN, September 19, 2023 – Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has received…
Read More » -
Spine
Karolinska Development’s portfolio company OssDsign has published a case report from the TOP FUSION study in a scientific journal
STOCKHOLM, SWEDEN, January 4, 2023 – Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has published…
Read More » -
Spine
Karolinska Development’s portfolio company OssDsign completes patient enrollment to the TOP FUSION study
STOCKHOLM, SWEDEN, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has enrolled…
Read More » -
Regulatory
Karolinska Development’s portfolio company Promimic receives FDA approval for its HAnano Surface® on a spinal implant
STOCKHOLM – August 28, 2019. Karolinska Development’s portfolio company Promimic today announced that the company’s first spinal device utilizing HAnano Surface…
Read More »